SCHEMBL476920

SCHEMBL476920

CC(C)[C@@H]1CC[C@]2(C)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A1 Q14973 1/20 0.73
GPBAR1 Q8TDU6 6/20 0.72
PRKCD Q05655 1/20 0.72
PTPN1 P18031 6/20 0.67
TOP2A P11388 2/20 0.67
CES2 O00748 1/20 0.67
CES1 P23141 1/20 0.67
NR1H4 Q96RI1 2/20 0.63
USP2 O75604 2/20 0.52
LMNA P02545 2/20 0.52
HIF1A Q16665 2/20 0.52
NT5E P21589 2/20 0.52
RELA Q04206 1/20 0.52
ALB P02768 2/20 0.51
AKR1B10 O60218 1/20 0.51
POLB P06746 1/20 0.51
GLI1 P08151 1/20 0.51
AKR1B1 P15121 1/20 0.51
DPP4 P27487 1/20 0.51
RORC P51449 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476921 1.00 SLC10A1 (0.73) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL13403268 1.00 SLC10A1 (0.73) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL13384623 1.00 SLC10A1 (0.73) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL14134573 0.88 SLC10A1 (0.66) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL17124238 0.87 PTPN1 (0.62) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL17817073 0.86 SLC10A1 (0.55) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL17832964 0.85 SLC10A1 (0.54) SLC10A1GPBAR1PRKCDPTPN1TOP2A
SCHEMBL17817075 0.85 SLC10A1 (0.54) SLC10A1GPBAR1PRKCDPTPN1TOP2A
Dihydrobetulin SCHEMBL24223727 0.84 SLC10A1 (1.00) SLC10A1GPBAR1PRKCDPTPN1TOP2A
Dihydrobetulin SCHEMBL22571117 0.84 SLC10A1 (1.00) SLC10A1GPBAR1PRKCDPTPN1TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021072473-A1 ANTIMICROBIALS AS FEED PRESERVATIVES IRP Health Pty Ltd (AU) 2021-04-22 WO claimed
WO-2021072473-A1 ANTIMICROBIALS AS FEED PRESERVATIVES IRP Health Pty Ltd (AU) 2021-04-22 WO disclosed
CN-104039396-A PERSONAL CARE COMPOSITIONS COMPRISING A pH TUNEABLE GELLANT AND METHODS OF USING PROCTER & GAMBLE 2014-09-10 CN disclosed
CN-103930167-A Personal care compositions comprising a di-amido gellant and methods of using PROCTER & GAMBLE 2014-07-16 CN disclosed
CN-103619308-A Personal care compositions comprising shaped abrasive particles PROCTER & GAMBLE 2014-03-05 CN disclosed
CN-101480419-B Polysaccharide extract of Periploca forrestii Schltr, and preparation method thereof INST PHARM & TOXICOLOGY AMMS 2013-07-03 CN disclosed
EP-2088152-B1 N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT INST NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) 2012-02-01 EP disclosed
US-20100087539-A1 N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT INSTITUT NEFTEKHIMII I KATALIZA ROSSIISKOI AKADEMII NAUK (RU) 2010-04-08 US disclosed
EP-2088152-A1 N'-{N-[3-OXO-LUPEN-28-OYL]-9-AMINONONANOYL}-3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT Institut Neftekhimii I Kataliza Rossiiskoi Akademii Nauk (RU) 2009-08-12 EP disclosed
CN-101480419-A Polysaccharide extract of Periploca forrestii Schltr, pharmaceutical composition containing the same as well as preparation method and application thereof POISON MED INST PLA MED ACAD (CN) 2009-07-15 CN disclosed
CN-101198342-A Composition for inducing sleep comprising essential oils as active ingredients, a percutaneous pharmaceutical agent comprising thereof, and a process for producing thereof NATURE TECHNOLOGY INC (JP) 2008-06-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087539-A1 N'--3-AMINO-3-PHENYLPROPEONIC ACID AND THE PHARMACEUTICALLY ACCEPTABLE DERIVATIVES THEREOF, A METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A MEDICINAL AGENT GART, DNPEP, IL4I1 SLC10A1 893/4885GPBAR1 516/4885PRKCD 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.